Italy cardiovascular disease therapeutics market is projected to grow from $3.9 Bn in 2022 to $6.5 Bn in 2030 with a CAGR of 6.72% for the year 2022-2030. The rising elderly population and hence the growing incidences of cardiovascular diseases in Italy are responsible for the growth of the market. The Italy cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Meda Pharma, Truffini & Reggè Farmaceutici, and Bristol-Myers Squibb are the major players in the Italy cardiovascular disease therapeutics market.
The New Zealand breast cancer therapeutics market is witnessing a growth of $xx Bn in 2022 with a CAGR of xx% for the year 2022-2030 and $xx Bn in 2030 due to market drivers like increasing investments in breast cancer treatments and growing awareness about breast cancer. The market is segmented by therapy, by cancer type, and by distribution channel. Alaron Products Limited, Bristol-Myers Squibb Co., and Eli Lilly and Co. are major companies in the New Zealand breast cancer therapeutics market.
Turkey's cardiovascular disease therapeutics market is expected to witness growth from $1.3 Bn in 2022 to $2.3 Bn in 2030 with a CAGR of 7.72% for the forecasted year 2022-30. due to the rising demand for cardiovascular therapeutics and the introduction of newer drugs and their launches in Turkey. The Turkey cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end user. Mirfarma, Farmazon, and Novartis are the major players in the Turkey cardiovascular disease therapeutics market.
Canada Dermatological Therapeutics Market is at around $3.28 Bn in 2023 and is projected to reach $5.84 Bn in 2030, exhibiting a CAGR of 8.6% during the forecast period. The market is growing due to factors such as the rising prevalence of skin disorders, the aging population, and technological developments. The market is dominated by key players like Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
The Vietnam Exosome Research Market was valued at $0.8 Mn in 2023 and is projected to grow at a CAGR of 16.23% from 2023 to 2023, to $2.4 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, QIAGEN, Lonza among others.
The UAE Exosome Research Market was valued at $0.8 Mn in 2023 and is projected to grow at a CAGR of 17% from 2023 to 2023, to $2.5 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, increasing advanced applications of exosomes. The industry is primarily dominated by players such as ExoCel Bio,Global Pharma, Modern Pharmaceuticals LLC, Epygen Biotech, Thermo Fisher Scientific, CellSave among others.
The Singapore Exosome Research Market was valued at $0.2 Mn in 2023 and is projected to grow at a CAGR of 16.6% from 2023 to 2023, to $0.6 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, increasing advanced applications of exosomes. The industry is primarily dominated by players such as Allozymes, Albatroz, Hitachi Chemical Diagnostics Inc., Qiagen, Gero, Lonza Group Ltd among others.
The India Clinical Nutrition for Diabetes Care Market was valued at $39.10 Mn in 2023 and is predicted to grow at a CAGR of 7.78% from 2023 to 2030, to $66.06 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Amway India, Pfizer Inc., and Zoic Pharmaceuticals among others.
The South Africa Clinical Nutrition for Diabetes Care Market was valued at $13.98 Mn in 2023 and is predicted to grow at a CAGR of 6.01% from 2023 to 2030, to $21.03 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Abbott Nutrition, Cipla, and Novo Nordisk among others.
The Kenya Clinical Nutrition for Diabetes Care Market was valued at $1.51 Mn in 2023 and is predicted to grow at a CAGR of 5.88% from 2023 to 2030, to $2.25 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Novo Nordisk, Solace Nutrition, and Abbott Nutrition among others.
The Egypt Clinical Nutrition for Diabetes Care Market was valued at $6.02 Mn in 2023 and is predicted to grow at a CAGR of 6.28% from 2023 to 2030, to $9.22 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Sanofi, Pharco Pharmaceuticals, and Novo Nordisk among others.
The Vietnam Clinical Nutrition for Diabetes Care Market was valued at $10.75 Mn in 2023 and is predicted to grow at a CAGR of 5.01% from 2023 to 2030, to $15.14 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Abbott Nutrition, Roche Diabetes Care, Sanofi and Novo Nordisk among others.
The Singapore Clinical Nutrition for Diabetes Care Market was valued at $2.58 Mn in 2023 and is predicted to grow at a CAGR of 5.38% from 2023 to 2030, to $3.72 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Nutribio, Pfizer Inc., and Novo Nordisk among others.
The Philippines Clinical Nutrition for Diabetes Care Market was valued at $4.73 Mn in 2023 and is predicted to grow at a CAGR of 5.28% from 2023 to 2030, to $6.78 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are United Laboratories, Inc. (Unilab), Zuellig Pharma, Sanofi, and Novo Nordisk among others.
The Malaysia Clinical Nutrition for Diabetes Care Market was valued at $3.46 Mn in 2023 and is predicted to grow at a CAGR of 4.98% from 2023 to 2030, to $4.86 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, B.Braun, Novo Nordisk, and Perrigo Company among others.
The Japan Clinical Nutrition for Diabetes Care Market was valued at $133.64 Mn in 2023 and is predicted to grow at a CAGR of 5.28% from 2023 to 2030, to $191.58 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Abbott Nutrition, Eli Lily, Danone, AgaMatrix Inc., and among others.
The Indonesia Clinical Nutrition for Diabetes Care Market was valued at $12.90 Mn in 2023 and is predicted to grow at a CAGR of 4.78% from 2023 to 2030, to $17.89 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Danone SA, Perrigo Company, and Abbott Nutrition among others.
The China Clinical Nutrition for Diabetes Care Market was valued at $172.83 Mn in 2023 and is predicted to grow at a CAGR of 6.28% from 2023 to 2030, to $264.72 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nutreco, Sanofi SA, Danone Nutricia, and Abbott Nutrition among others.
The UK Clinical Nutrition for Diabetes Care Market was valued at $55.90 Mn in 2023 and is predicted to grow at a CAGR of 2.78% from 2023 to 2030, to $67.73 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Abbott Nutrition, Nualtra, Clinova Ltd, and Novo Nordisk among others.
The Spain Clinical Nutrition for Diabetes Care Market was valued at $41.50 Mn in 2023 and is predicted to grow at a CAGR of 3.78% from 2023 to 2030, to $53.80 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Mediquo, Sweetcare, Pfizer Inc., and Mefood Omics among others.
The Germany Clinical Nutrition for Diabetes Care Market was valued at $78.69 Mn in 2023 and is predicted to grow at a CAGR of 2.98% from 2023 to 2030, to $96.65 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Fresenius Kabi, Baxter International, and Novo Nordisk among others.
The France Clinical Nutrition for Diabetes Care Market was valued at $59.13 Mn in 2023 and is predicted to grow at a CAGR of 3.78% from 2023 to 2030, to $76.66 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Nutribio, Sanofi S.A., and Baxter International Inc. among others.
The Saudi Arabia Exosome Research Market was valued at $1.1 Mn in 2023 and is projected to grow at a CAGR of 17.23% from 2023 to 2023, to $3.3 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Hologic Inc., Luminex Corporation, QIAGEN, Agilent Technologies among others.
The Brazil Clinical Nutrition for Diabetes Care Market was valued at $53.75 Mn in 2023 and is predicted to grow at a CAGR of 5.78% from 2023 to 2030, to $79.65 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Nutribio, Pfizer Inc., and Novo Nordisk among others.
The UAE Clinical Nutrition for Diabetes Care Market was valued at $10.75 Mn in 2023 and is predicted to grow at a CAGR of 5.78% from 2023 to 2030, to $15.93 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestlé Health Science, Eli Lily, Baxter International, Boehringer Ingelheim, and among others.